Back

Long-term cost-effectiveness of digitoxin in heart failure with reduced ejection fraction analyzed in DIGIT-HF

29 August 2026 (18:15 - 18:30)
Organised by: Logo
Congress Presentation Part of: Digitalis glycosides in heart failure: back to the future! Pharmacotherapy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Priyanka Boettger

Justus-Liebig University of Giessen, Giessen (Germany)

3 More presentations in this session

Presentation thumbnail
Early or late, benefits of digoxin reconsidered in HFrEF: Insights from the Digitalis Investigation Group Trial (DIG)
Doctor M. Chimura (Glasgow, GB)
Slides Video
Presentation thumbnail
Efficacy of digitoxin over time in patients with HFrEF: further analysis of DIGIT-HF
Professor U. Bavendiek (Hannover, DE)
Slides Video
Presentation thumbnail
Low-dose Digoxin in Women and Men with Heart Failure: Data from DECISION
Professor D. van Veldhuisen (Groningen, NL)
Slides Video

Access the full session

Session thumbnail
Digitalis glycosides in heart failure: back to the future!
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 18:15 CET
You may be interested in
thumbnail
Congress Presentation
NET-COST-HFrEF: A NETwork meta-analysis with COST-effectiveness evaluation in HFrEF
11 May 2026
thumbnail
Congress Presentation
Discussant review - DIGIT-HF
29 August 2025
thumbnail
Congress Presentation
Cardiovascular disease prevention: the economic imperative
29 August 2026
thumbnail
Congress Presentation
A value-based analysis of the systematic use of dapagliflozin in patients with heart failure
29 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources